Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StrykerLTS:0R2S +4.79%92 Receivables Turnover is 1.58 as of Mar. 2026. GuruFocus rates LTS:0R2S with a GF Score™ of 92/100 and a GF Value™ of $411.59 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 811 Medical Devices & Instruments companies, Stryker ranks better than 63.13% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Stryker's Revenue for the
three
months ended in Mar. 2026 was $6,020 Mil. Stryker's average Accounts Receivable for the
three
months ended in Mar. 2026 was $3,805 Mil.
Hence, Stryker's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.58.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Stryker Receivables Turnover Related Terms
Stryker Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Stryker's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R2S vs MDT, ABT, BSX: Receivables Turnover Comparison
For the Medical Devices subindustry, Stryker's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stryker Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stryker's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Stryker's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stryker (LTS:0R2S) has a Receivables Turnover of 1.58 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Stryker and its competitors. According to the industry distribution chart, Stryker ranks #299 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 36.9%.
Is Stryker's Receivables Turnover too high?
Stryker's current Receivables Turnover is 1.58. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Stryker's value of 1.58 is 71.3% below this industry median. Based on the distribution chart, Stryker ranks #299 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stryker has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stryker's Receivables Turnover compare to MDT and ABT?
According to the Medical Devices & Instruments industry distribution chart, Stryker ranks #299 out of 811 companies for Receivables Turnover. This puts Stryker in the upper half of its industry. The industry median Receivables Turnover is 5.51. Stryker's value of 1.58 is 71.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stryker's current Receivables Turnover of 1.58 is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Stryker and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stryker's current Receivables Turnover is 1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stryker stock overvalued right now?
Based on GuruFocus' analysis, Stryker (LTS:0R2S) is currently considered Modestly Undervalued. The stock's GF Value™ is $411.59, compared to a current price of $329.05 — trading 20.1% below its estimated fair value. The current Receivables Turnover is 1.58 and 71.3% below the Medical Devices & Instruments industry median of 5.51. Stryker's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Stryker (LTS:0R2S), the current Receivables Turnover is 1.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stryker (LTS:0R2S) Overvalued in 2026?
Based on GuruFocus' analysis, Stryker stock appears to be undervalued.
The current stock price of $329.05 is trading 20.1% below its estimated GF Value™ of $411.59.
GuruFocus considers Stryker to be Modestly Undervalued.
Key valuation signals for LTS:0R2S:
Receivables Turnover: 1.58
GF Value™: $411.59 vs. price of $329.05 (20.1% below fair value)
Industry Position: 71.3% below the Medical Devices & Instruments median (#299 of 811)
No single metric tells the full story. See the LTS:0R2S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
92GF Score
Get the complete analysis for LTS:0R2S
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2S has been successfully added to your 
